The National Reining Horse Association (NRHA) is excited to announce the continuing partnership of Adequan® i.m. (polysulfated glycosaminoglycan), the Official Joint Therapy of NRHA, title sponsor of the Adequan® North American Affiliate Championship (NAAC) and the named sponsor of the Adequan® Championship Arena during the NRHA-owned events. Adequan® i.m. has been a loyal NRHA Corporate Partner continuously since 2005 and with their renewal will continue through 2018.
Maintaining health of reining horses
Maintaining the health and soundness of reining horses is the key to success in NRHA show pens, and Adequan® i.m. is a veterinarian-trusted name in the fight against equine degenerative joint disease.
© 2015 by Mike Berg
âThe sport of Reining is a core discipline we are excited to continue supporting,â stated Allyn Mann, Director of Luitpold Animal Health, the makers of Adequan® i.m. âWe are pleased with the growth of the association, especially with the Adequan® North American Affiliate Championship held in conjunction with the Reining Futurity. Looking forward to continuing the journey with the NRHA.â
Maintaining the health and soundness of reining horses is the key to success in NRHA show pens. Adequan® i.m. is a veterinarian-trusted name in the fight against equine degenerative joint disease. Luitpold Animal Health is committed to advancing the cause of better animal health through scientifically proven and FDA-approved products.
Adequan® i.m. is the only FDA-approved intramuscular polysulfated glycosaminoglycan. Early treatment with Adequan® i.m. can stop the destructive disease cycle, reverse degenerative joint disease and improve joint function. If your equine athlete or companion horse is experiencing degenerative joint disease, speak to your veterinarian and find out if Adequan® i.m., âThe Winning Formula for Champions,â can benefit your horse.
Todd Barden, Sr. Director of Business Development said, âOur partnership with Adequan® has truly been a blessing for NRHA. No one in the equine world has more passion for Reining than Allyn Mann. It is through his tireless efforts that Adequan® i.m. has so successfully supported the growth of Reining.
In particular, their support at the Affiliate level cannot be matched. From their title sponsorship of the Adequan® NAAC, to the Adequan® 500 program, they have made a significant impact. We look forward to continuing our partnership with such an impassioned industry leader and company.â
NRHA has over 850 NRHA-approved shows worldwide with nearly $14 million in competition purses annually. Adequan® i.m. will be an official NRHA Corporate Partner of the NRHA Futurity & Adequan® North American Affiliate Championship Show, NRHA Derby and the North American Affiliate Regional Championships.
Incorporated in 1966, the National Reining Horse Association is the standard-setting body for the sport of Reining. NRHA, with their International Headquarters in Oklahoma City, is responsible for promoting the sport of Reining and working to ensure the highest standards of competition.
Adequan® i.m. Brief Summary
Brief Summary Indications: For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
There are no known contraindications to the use of intramuscular Adequan® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses.
WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Each 5 mL contains 500 mg Polysulfated Glycosaminoglycan. SEE PRODUCT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION at www.adequan.com.
Adequan® is a registered trademark of Luitpold Pharmaceuticals, Inc. ©LUITPOLD PHARMACEUTICALS, INC., Animal Health Division, Shirley, NY 11967.
Article by Christina Brezack